Cargando…
Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics
BACKGROUND: Monitoring bladder cancer over time requires invasive and costly procedures. Less invasive approaches are required using readily available biological samples such as urine. In this study, we demonstrate a method for longitudinal analysis of the urine proteome to monitor the disease cours...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842762/ https://www.ncbi.nlm.nih.gov/pubmed/36646893 http://dx.doi.org/10.1038/s43856-023-00238-4 |
_version_ | 1784870217129656320 |
---|---|
author | Carvalho, Luís Botelho Capelo, José Luis Lodeiro, Carlos Dhir, Rajiv Pinheiro, Luis Campos López-Fernández, Hugo Martins, Gonçalo Medeiros, Mariana Díaz, Fernando Santos, Hugo Miguel |
author_facet | Carvalho, Luís Botelho Capelo, José Luis Lodeiro, Carlos Dhir, Rajiv Pinheiro, Luis Campos López-Fernández, Hugo Martins, Gonçalo Medeiros, Mariana Díaz, Fernando Santos, Hugo Miguel |
author_sort | Carvalho, Luís Botelho |
collection | PubMed |
description | BACKGROUND: Monitoring bladder cancer over time requires invasive and costly procedures. Less invasive approaches are required using readily available biological samples such as urine. In this study, we demonstrate a method for longitudinal analysis of the urine proteome to monitor the disease course in patients with bladder cancer. METHODS: We compared the urine proteomes of patients who experienced recurrence and/or progression (n = 13) with those who did not (n = 17). We identified differentially expressed proteins within various pathways related to the hallmarks of cancer. The variation of such pathways during the disease course was determined using our differential personal pathway index (dPPi) calculation, which could indicate disease progression and the need for medical intervention. RESULTS: Seven hallmark pathways are used to develop the dPPi. We demonstrate that we can successfully longitudinally monitor the disease course in bladder cancer patients through a combination of urine proteomic analysis and the dPPi calculation, over a period of 62 months. CONCLUSIONS: Using the information contained in the patient’s urinary proteome, the dPPi reflects the individual’s course of bladder cancer, and helps to optimise the use of more invasive procedures such as cystoscopy. |
format | Online Article Text |
id | pubmed-9842762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98427622023-01-18 Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics Carvalho, Luís Botelho Capelo, José Luis Lodeiro, Carlos Dhir, Rajiv Pinheiro, Luis Campos López-Fernández, Hugo Martins, Gonçalo Medeiros, Mariana Díaz, Fernando Santos, Hugo Miguel Commun Med (Lond) Article BACKGROUND: Monitoring bladder cancer over time requires invasive and costly procedures. Less invasive approaches are required using readily available biological samples such as urine. In this study, we demonstrate a method for longitudinal analysis of the urine proteome to monitor the disease course in patients with bladder cancer. METHODS: We compared the urine proteomes of patients who experienced recurrence and/or progression (n = 13) with those who did not (n = 17). We identified differentially expressed proteins within various pathways related to the hallmarks of cancer. The variation of such pathways during the disease course was determined using our differential personal pathway index (dPPi) calculation, which could indicate disease progression and the need for medical intervention. RESULTS: Seven hallmark pathways are used to develop the dPPi. We demonstrate that we can successfully longitudinally monitor the disease course in bladder cancer patients through a combination of urine proteomic analysis and the dPPi calculation, over a period of 62 months. CONCLUSIONS: Using the information contained in the patient’s urinary proteome, the dPPi reflects the individual’s course of bladder cancer, and helps to optimise the use of more invasive procedures such as cystoscopy. Nature Publishing Group UK 2023-01-16 /pmc/articles/PMC9842762/ /pubmed/36646893 http://dx.doi.org/10.1038/s43856-023-00238-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Carvalho, Luís Botelho Capelo, José Luis Lodeiro, Carlos Dhir, Rajiv Pinheiro, Luis Campos López-Fernández, Hugo Martins, Gonçalo Medeiros, Mariana Díaz, Fernando Santos, Hugo Miguel Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title | Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title_full | Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title_fullStr | Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title_full_unstemmed | Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title_short | Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
title_sort | pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842762/ https://www.ncbi.nlm.nih.gov/pubmed/36646893 http://dx.doi.org/10.1038/s43856-023-00238-4 |
work_keys_str_mv | AT carvalholuisbotelho pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT capelojoseluis pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT lodeirocarlos pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT dhirrajiv pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT pinheiroluiscampos pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT lopezfernandezhugo pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT martinsgoncalo pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT medeirosmariana pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT diazfernando pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics AT santoshugomiguel pathwayguidedmonitoringofthediseasecourseinbladdercancerwithlongitudinalurineproteomics |